The USFDA has approved revumenib for treating relapsed or refractory acute leukemia in adult and pediatric patients one year and older. Revumenib, a menin inhibitor, is specifically indicated for acute leukemia patients with a lysine methyltransferase 2A gene translocation. Clinical evidence In a clinical trial conducted on 104 adult and pediatric patients, revumenib achieved a 21.2% rate of complete remission plus complete remission with partial hematologic recovery with a median duration of 6.4 months.
In addition, among the 83 patients reliant on RBC and/or platelet transfusions at baseline, 14% became independent of these transfusions during any 56-day period following treatment initiation. Dosage and administration Available as tablets Orally twice daily fasted or with a low-fat meal Warnings and precautions QTc interval prolongation Embryo-fetal toxicity Adverse reactions –…
